These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17963827)

  • 1. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
    Patsner B
    Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
    [No Abstract]   [Full Text] [Related]  

  • 2. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
    Markman M
    Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of cancer drugs on survival: often poorly evaluated.
    Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current topic of intraperitoneal infusions for treatment of ovarian cancer].
    Fujiwara K
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):224-227. PubMed ID: 18372511
    [No Abstract]   [Full Text] [Related]  

  • 6. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
    Rao G; Crispens M; Rothenberg ML
    J Clin Oncol; 2007 Jul; 25(20):2867-72. PubMed ID: 17617517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ethics of early stopping rules: who is protecting whom?
    Cannistra SA
    J Clin Oncol; 2004 May; 22(9):1542-5. PubMed ID: 15117977
    [No Abstract]   [Full Text] [Related]  

  • 10. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J; Yoshida N
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pros and cons for systemic therapy in recurrent ovarian cancer.
    Oskay-Ozcelik G; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.
    Mietlowski W; Wang J
    Contemp Clin Trials; 2007 Sep; 28(5):674. PubMed ID: 17449334
    [No Abstract]   [Full Text] [Related]  

  • 15. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel endpoints in phase III clinical trials.
    Sargent DJ
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):21-3. PubMed ID: 16166962
    [No Abstract]   [Full Text] [Related]  

  • 17. Trial watch: pivotal oncology trials: outlook for Q2 2009.
    Nehring R
    Nat Rev Drug Discov; 2009 Apr; 8(4):266. PubMed ID: 19337264
    [No Abstract]   [Full Text] [Related]  

  • 18. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 19. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.
    Lefebvre JL; Ang KK;
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1293-303. PubMed ID: 19306746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial treatment for ovarian cancer].
    Suzuki M; Fujiwara H; Takei Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):224-9. PubMed ID: 19263611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.